FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Abstract Purpose Glioma is the most common primary intracranial tumor. Owing to the poor prognosis associated with high-grade gliomas, there is an urgent need to identify biomarkers related to prognosis and treatment sensitivity. Here, we analyze the expression of FXYD2 mRNA in gliomas, and explore...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kaijia Zhou, Tao Jiang, Yanwei Liu, Zheng Zhao, Lijie Huang, Guanzhang Li
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	FXYD2 Glioma Chemotherapy Prognosis Molecular profile Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ec583aa011414843a3d061c175e3fe74
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec583aa011414843a3d061c175e3fe74
record_format	dspace
spelling	oai:doaj.org-article:ec583aa011414843a3d061c175e3fe742021-11-14T12:13:22ZFXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide10.1186/s12883-021-02476-21471-2377https://doaj.org/article/ec583aa011414843a3d061c175e3fe742021-11-01T00:00:00Zhttps://doi.org/10.1186/s12883-021-02476-2https://doaj.org/toc/1471-2377Abstract Purpose Glioma is the most common primary intracranial tumor. Owing to the poor prognosis associated with high-grade gliomas, there is an urgent need to identify biomarkers related to prognosis and treatment sensitivity. Here, we analyze the expression of FXYD2 mRNA in gliomas, and explore its clinical prognostic value and significance in this disease. Methods Clinical features, FXYD2 mRNA expression levels, and survival data were analyzed for 516 glioma patients from the Chinese Glioma Genome Map Project, 481 from the cancer genome map datbase and 268 from the molecular braintumor database. The expression patterns for FXYD2 mRNA were compared using the chi-square test, and overall survival (OS) of glioma patients was evaluated according to FXYD2 mRNA expression levels. The factors affecting glioma survival were evaluated by Cox univariate and multivariate regression analysis. Results FXYD2 mRNA expression was related to the grade of gliomas. The higher the level, the lower the expression. Meanwhile related to the pathological classification of gliomas. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted was higher than Astrocytoma, IDH-mutant, higher than Glioblastoma, IDH-wildtype. Moreover, temozolomide (TMZ) chemotherapy was found to be an independent factor affecting survival in patients with high FXYD2 mRNA expression, but not in patients with low expression. Conclusion FXYD2 mRNA expression represents a new independent factor affecting the survival of glioma patients and may serve as an independent prognostic indicator to predict the sensitivity of gliomas to TMZ.Kaijia ZhouTao JiangYanwei LiuZheng ZhaoLijie HuangGuanzhang LiBMCarticleFXYD2GliomaChemotherapyPrognosisMolecular profileNeurology. Diseases of the nervous systemRC346-429ENBMC Neurology, Vol 21, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	FXYD2 Glioma Chemotherapy Prognosis Molecular profile Neurology. Diseases of the nervous system RC346-429
spellingShingle	FXYD2 Glioma Chemotherapy Prognosis Molecular profile Neurology. Diseases of the nervous system RC346-429 Kaijia Zhou Tao Jiang Yanwei Liu Zheng Zhao Lijie Huang Guanzhang Li FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
description	Abstract Purpose Glioma is the most common primary intracranial tumor. Owing to the poor prognosis associated with high-grade gliomas, there is an urgent need to identify biomarkers related to prognosis and treatment sensitivity. Here, we analyze the expression of FXYD2 mRNA in gliomas, and explore its clinical prognostic value and significance in this disease. Methods Clinical features, FXYD2 mRNA expression levels, and survival data were analyzed for 516 glioma patients from the Chinese Glioma Genome Map Project, 481 from the cancer genome map datbase and 268 from the molecular braintumor database. The expression patterns for FXYD2 mRNA were compared using the chi-square test, and overall survival (OS) of glioma patients was evaluated according to FXYD2 mRNA expression levels. The factors affecting glioma survival were evaluated by Cox univariate and multivariate regression analysis. Results FXYD2 mRNA expression was related to the grade of gliomas. The higher the level, the lower the expression. Meanwhile related to the pathological classification of gliomas. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted was higher than Astrocytoma, IDH-mutant, higher than Glioblastoma, IDH-wildtype. Moreover, temozolomide (TMZ) chemotherapy was found to be an independent factor affecting survival in patients with high FXYD2 mRNA expression, but not in patients with low expression. Conclusion FXYD2 mRNA expression represents a new independent factor affecting the survival of glioma patients and may serve as an independent prognostic indicator to predict the sensitivity of gliomas to TMZ.
format	article
author	Kaijia Zhou Tao Jiang Yanwei Liu Zheng Zhao Lijie Huang Guanzhang Li
author_facet	Kaijia Zhou Tao Jiang Yanwei Liu Zheng Zhao Lijie Huang Guanzhang Li
author_sort	Kaijia Zhou
title	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
title_short	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
title_full	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
title_fullStr	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
title_full_unstemmed	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
title_sort	fxyd2 mrna expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
publisher	BMC
publishDate	2021
url	https://doaj.org/article/ec583aa011414843a3d061c175e3fe74
work_keys_str_mv	AT kaijiazhou fxyd2mrnaexpressionrepresentsanewindependentfactorthataffectssurvivalofgliomapatientsandpredictschemosensitivityofpatientstotemozolomide AT taojiang fxyd2mrnaexpressionrepresentsanewindependentfactorthataffectssurvivalofgliomapatientsandpredictschemosensitivityofpatientstotemozolomide AT yanweiliu fxyd2mrnaexpressionrepresentsanewindependentfactorthataffectssurvivalofgliomapatientsandpredictschemosensitivityofpatientstotemozolomide AT zhengzhao fxyd2mrnaexpressionrepresentsanewindependentfactorthataffectssurvivalofgliomapatientsandpredictschemosensitivityofpatientstotemozolomide AT lijiehuang fxyd2mrnaexpressionrepresentsanewindependentfactorthataffectssurvivalofgliomapatientsandpredictschemosensitivityofpatientstotemozolomide AT guanzhangli fxyd2mrnaexpressionrepresentsanewindependentfactorthataffectssurvivalofgliomapatientsandpredictschemosensitivityofpatientstotemozolomide
_version_	1718429380073488384

FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Ejemplares similares